奥氮平与利培酮治疗脑器质性精神障碍疗效和安全性比较  

Efficacy and Safety Comparison of Olanzapine and Risperidone in Treating Brain Organic Mental Disorders

作　　者：徐兴红[1] 邓丽凤[1] 

机构地区：[1]重庆市精神卫生中心,重庆400036

出　　处：《中国药业》2017年第8期43-46,共4页China Pharmaceuticals

摘　　要：目的比较奥氮平与利培酮治疗脑器质性精神障碍的临床疗效和安全性。方法按随机数字表法将60例脑器质性精神障碍患者分为奥氮平组和利培酮组,各30例,分别口服奥氮平和利培酮治疗,疗程均为6周。治疗前与治疗第2,4,6周末用阳性与阴性症状量表(PANSS)评定疗效,用副反应量表(TESS)评定不良反应发生情况。结果治疗6周末,两组患者PANSS评分均较治疗前显著下降(P<0.01);两组患者的总显效率及总有效率无显著性差异(P>0.05);奥氮平组锥体外系反应(EPS)发生率显著低于利培酮组(P<0.05),失眠发生率显著低于利培酮组(P<0.01),两组患者其他不良反应发生率比较,差异均无统计学意义(P>0.05)。结论奥氮平与利培酮对器质性精神障碍均有显著疗效,安全性高,依从性好,临床可按需选用。Objective To compare the clinical efficacy and safety of Olanzapine and Risperidone in the treatment of brain organic men-tal disorders. Methods A total of 60 patients with brain organic mental disorder patients were selected and divided into the Olanzapine group and Risperidone group in accordance with the random number table method,30 cases in each group. Oral treatment of the re-spective drugs were taken,and both groups were treated for 6 weeks. Before treatment and 2,4,6 weeks after treatment,the positive and negative symptoms scale（PANSS）was used to evaluate the efficacy,and the adverse reaction was assessed by TESS. Results After the 6-weeks treatment,the PANSS scores of the two groups were significantly lower than those before treatment（P 〈 0. 01）. There was no significant difference between the two groups in the total efficiency rate and the total effective rate（P 〉 0. 05）. The incidence of EPS in the Olanzapine group was significantly lower than that in the Risperidone group（P 〈 0. 05）,and the incidence of insomnia was sig-nificantly lower than the Risperidone group（P 〈 0. 01）. There was no significant difference in the incidence of other adverse reactions between the two groups（P 〉 0. 05）. Conclusion Olanzapine and Risperidone have a significant effect on organic mental disorders with high safety and good compliance. Thus,we can choose either of them according to the clinical needs.

关 键 词：器质性精神障碍 奥氮平 利培酮 疗效 安全性 

分 类 号：R969.4[医药卫生—药理学] R971.4[医药卫生—药学]